(NasdaqGM:FATE), SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) […]

(NASDAQ:ADIL), GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock,

(NASDAQ:BTSG), LOUISVILLE, Ky., Feb. 03, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET

(NASDAQ:AMOD),(NASDAQ:AMODW),(NASDAQ:ACIW), CORNELIUS, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) — Alpha Modus Financial Services (“AMFS”), a division of Alpha Modus Holdings, Inc. (“Alpha Modus”) (NASDAQ: AMOD), has entered into a multi-year services agreement with ACI Worldwide (“ACI”) (NASDAQ: ACIW), a global leader in mission-critical real-time payments software, to support remittance and bill payment capabilities across the

eGain Announces Second Quarter 2026 Financial Results AI Knowledge Hub ARR Increases 27% Year Over Year GlobeNewswire February 03, 2026 SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) — eGain (Nasdaq: EGAN), a leading provider of AI-powered knowledge management solutions, today announced financial results for its fiscal 2026 second quarter ended December 31, 2025. “I am

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026 GlobeNewswire February 03, 2026 Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized

AvePoint to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 GlobeNewswire February 03, 2026 JERSEY CITY, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — AvePoint (NASDAQ: AVPT; SGX: AVP), the global leader in AI data protection, unifying data security, governance, and resilience, will report its fourth quarter and full year 2025 financial

Enphase Energy Reports Financial Results for the Fourth Quarter of 2025 GlobeNewswire February 03, 2026 FREMONT, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, announced today financial results for the fourth quarter of 2025, which included the summary below from its President and CEO, Badri Kothandaraman.

Amaze Announces Cancellation of Special Meeting of Stockholders GlobeNewswire February 03, 2026 NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today announced that its Special Meeting of Stockholders, which was scheduled for February 4, 2026, has been cancelled.

BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research GlobeNewswire February 03, 2026 POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the